Q-omics provides the consensus-scored MIR1269B profile across patient tissues and cancer cell-line models. MIR1269B expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR1269B is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR1269B RNA expression shows 7,306 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, LUSC, and GBM as cancer lineages where MIR1269B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1269B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1269B survival associations across molecular data types. MIR1269B RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1269B RNA expression–survival associations across cancer types. High MIR1269B expression shows unfavorable associations in UCEC, KIRP, LUSC, READ, THCA and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR1269B RNA expression.
This table summarizes MIR1269B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1269B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1269B shows lower tumor expression in LUSC. The LUSC box plot shows higher MIR1269B RNA expression in normal versus tumor tissue (log2 FC = −0.113, t-test p = .028).
This table shows molecular features associated with MIR1269B in patient tissues and cancer cell lines. In patient samples, MIR1269B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
